A Clinical Pharmacodynamic and Pharmacogenetic Study of OPB-51602 in Patients With Advanced Solid Tumours

National University Health System (NUHS)

Status: Unknown

Conditions: Advanced Solid Tumors

Treatments: Other: Biomarker

Study type: Observational

Funder types: Other

Identifiers

NCT01867073

PG01/04/11

Details and patient eligibility

About

OPB-51602 is a novel oral small molecule STAT3 inhibitor developed by Otsuka Pharmaceutical Company, Ltd, and is currently undergoing clinical investigation at the National University Health System (NUHS), Singapore. The proposed correlative pharmacodynamic and pharmacogenetic biomarker study is initiated and funded by the investigators, and will be conducted in conjunction with the extension phase I protocol of OPB-51602 in patients with advanced solid tumours (Study code 266-09-801-01/ DSRB protocol B/09/514). All biomarker and pharmacogenetic samples will be collected, stored and analysed at the local laboratory of the study site (Cancer Science Institute, National University Health System, Singapore, Dr Boon-Cher Goh).

Enrollment: 20 estimated patients

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Advanced Solid Tumor

Exclusion criteria

Non advanced solid tumor

Trial design

20 participants in 1 patient group

Advanced solid tumours

Treatment:

Other: Biomarker